Expression and Function of Group IIE Phospholipase A2 in Mouse Skin*

Recent studies using knock-out mice for various secreted phospholipase A2 (sPLA2) isoforms have revealed their non-redundant roles in diverse biological events. In the skin, group IIF sPLA2 (sPLA2-IIF), an “epidermal sPLA2” expressed in the suprabasal keratinocytes, plays a fundamental role in epidermal-hyperplasic diseases such as psoriasis and skin cancer. In this study, we found that group IIE sPLA2 (sPLA2-IIE) was expressed abundantly in hair follicles and to a lesser extent in basal epidermal keratinocytes in mouse skin. Mice lacking sPLA2-IIE exhibited skin abnormalities distinct from those in mice lacking sPLA2-IIF, with perturbation of hair follicle ultrastructure, modest changes in the steady-state expression of a subset of skin genes, and no changes in the features of psoriasis or contact dermatitis. Lipidomics analysis revealed that sPLA2-IIE and -IIF were coupled with distinct lipid pathways in the skin. Overall, two skin sPLA2s, hair follicular sPLA2-IIE and epidermal sPLA2-IIF, play non-redundant roles in distinct compartments of mouse skin, underscoring the functional diversity of multiple sPLA2s in the coordinated regulation of skin homeostasis and diseases.

Lipids constitute an essential component of skin homeostasis and diseases. The epidermis is a highly organized stratified epithelium having four distinctive layers comprising the innermost stratum basale, the stratum spinosum, the stratum granulosum, and the outermost stratum corneum (SC) 2 (1). The hair follicle, a skin appendage formed by interactions between epi-dermal keratinocytes committed to hair follicle differentiation and dermal fibroblasts committed to formation of the dermal papilla, undergoes repeated cycles of growth (anagen), regression (catagen), and rest (telogen) during life span (2). Nutritional insufficiency of essential fatty acids causes epidermal and hair abnormalities (1), and genetic mutations in several steps of skin lipid metabolism variably and often severely affect SC barrier function or hair cycling, thereby causing or exacerbating skin disorders such as ichthyosis, psoriasis, atopic dermatitis, and alopecia (3)(4)(5)(6). Linoleic acid (LA), by far the most abundant polyunsaturated fatty acid (PUFA) in the SC, is crucial for the formation of acylceramide, an essential component of the cornified lipid envelope (7,8). Fatty acids have also been implicated in SC acidification (9 -11). Furthermore, dysregulated production of lipid mediators derived from PUFAs or lysophospholipids can be linked to skin disorders such as hair loss, epidermal hyperplasia, dermatitis, and cancer (6,12,13).
Phospholipase A 2 (PLA 2 ) enzymes hydrolyze the sn-2 position of phospholipids to release fatty acids and lysophospholipids, which act as precursors of a variety of lipid mediators. Of the PLA 2 enzymes, cytosolic PLA 2 ␣ plays a central role in eicosanoid generation by selectively releasing arachidonic acid (AA) (14,15), and Ca 2ϩ -independent PLA 2 s are involved in energy metabolism and neurodegeneration (16,17). Although the biological roles of the secreted PLA 2 (sPLA 2 ) family have remained unclear over the past few decades, recent studies using mice gene-manipulated for sPLA 2 isoforms have revealed their diverse and non-redundant functions in immunity, host defense, atherosclerosis, obesity, cancer, and reproduction, etc. by driving unique lipid pathways in given extracellular microenvironments (18).
We have recently demonstrated that group IIF sPLA 2 (sPLA 2 -IIF) is expressed predominantly in the suprabasal epidermis and that its genetic deletion perturbs keratinocyte differentiation and activation, particularly under pathological conditions such as psoriasis and skin cancer (19). This action of sPLA 2 -IIF as an "epidermal sPLA 2 " depends at least in part on the generation of plasmalogen lysophosphatidylethanolamine (P-LPE; lysoplasmalogen), a unique lysophospholipid that can promote keratinocyte activation and epidermal hyperplasia. Beyond sPLA 2 -IIF, transgenic overexpression of sPLA 2 -IIA or -X causes alopecia and epidermal hyperplasia (20,21), although endogenous expression of these two sPLA 2 s as well as sPLA 2 -IB, -IID, and -V in mouse skin is low or almost undetectable (19). sPLA 2 -IIE is an isoform structurally most homologous to sPLA 2 -IIA (22,23). Although the expression, target phospholipids, and biological roles of sPLA 2 -IIE in vivo remained a mystery for more than a decade, we have recently shown that it is a diet-inducible, adipocyte-driven "metabolic sPLA 2 " that participates in metabolic regulation by acting on minor phospholipids in lipoprotein particles (24). In this study, we show for the first time that sPLA 2 -IIE is abundantly expressed in mouse skin, being enriched in hair follicles. Analyses of mice lacking sPLA 2 -IIE (Pla2g2e Ϫ/Ϫ ), in comparison with those lacking sPLA 2 -IIF (Pla2g2f Ϫ/Ϫ ), revealed distinct roles of these two sPLA 2 s in skin homeostasis and diseases.

Results
Expression of sPLA 2 -IIE in Mouse Skin-We have recently shown that sPLA 2 -IIE is highly expressed in hypertrophic adipocytes of obese mice (24). In a search of other mouse tissues in which sPLA 2 -IIE is expressed under steady-state conditions, we found that Pla2g2e mRNA (encoding sPLA 2 -IIE) was uniquely distributed in the uterus and skin at higher levels than in adipose tissue (Fig. 1A). The expression of sPLA 2 -IIE in the uterus had been reported previously (22), although Pla2g2e Ϫ/Ϫ mice, both male and female, did not show reproductive abnormality (data not shown). Therefore, in this study, we focused on the expression and function of this sPLA 2 in mouse skin.
As reported previously (19), Pla2g2f mRNA (encoding sPLA 2 -IIF) was expressed abundantly in mouse dorsal skin throughout the peri-to postnatal period (Fig. 1B). We noticed that, although the skin expression of Pla2g2e was low before birth, it increased markedly during P5-15, even exceeding the expression of Pla2g2f (Fig. 1B). Thereafter, the expression of Pla2g2e declined to nearly the basal level during P20 -25 and then increased again to a level higher than that of Pla2g2f at P30. The periodic pattern of Pla2g2e expression appeared to coincide with the hair cycle, which involves repeated cycles of growth (anagen; P0 -15), regression (catagen; P15-20), rest  3). B, quantitative RT-PCR of sPLA 2 s in mouse skin over E17.5 to P30, with Rn18s as an internal control. C, quantitative RT-PCR of three sPLA 2 s in the epidermal and hair follicular fractions separated by microdissection, with Actb as an internal control. N.D., not detected. B and C, two representative results (Exp. 1 and 2) are shown. D, quantitative RT-PCR of sPLA 2 s and Krt1 in mouse keratinocytes with or without Ca 2ϩ -induced differentiation in primary culture, as detailed under "Experimental Procedures" (n ϭ 3-5). Values are mean Ϯ S.E., *, p Ͻ 0.05, and **, p Ͻ 0.01.
To address this issue, we separated the epidermis and hair follicles from frozen sections of mouse dorsal skin at P8 by microdissection. As expected (19), Pla2g2f was distributed in the epidermal fraction almost exclusively, whereas Pla2g2e was expressed in both fractions, with more abundant expression in the hair follicle fraction than in the epidermal fraction (Fig. 1C). Although Pla2g10 (encoding sPLA 2 -X) has been reported to be expressed in hair follicles in correlation with the hair cycle (21), its hair follicle expression, relative to that of Pla2g2e, was nearly negligible (Fig. 1C). Expression levels of other sPLA 2 s (IB, IID, and V) in hair follicles were minimal (19). Thus, sPLA 2 -IIE is the predominant sPLA 2 expressed in hair follicles during anagen.
Because a substantial level of Pla2g2e expression was also detected in the epidermal fraction ( Fig. 1C), we examined its expression in epidermal keratinocytes in primary culture. Ca 2ϩ -induced differentiation of primary keratinocytes from newborn WT mice resulted in robust induction of Pla2g2f in parallel with that of the keratinocyte differentiation marker Krt1 (Fig. 1D), as reported previously (19). In contrast, Pla2g2e expression in cultured keratinocytes was constant regardless of the presence of Ca 2ϩ (Fig. 1D). These results suggest that, in contrast to sPLA 2 -IIF that is induced in differentiated keratinocytes (19), sPLA 2 -IIE is constantly expressed in undifferentiated basal keratinocytes.
Consistent with the preferential distribution of Pla2g2e in hair follicles, in situ hybridization of Pla2g2e in mouse dorsal skin at 4 weeks, a period corresponding to the next anagen, confirmed its distribution in growing hair follicles but not in the dermal papilla (Fig. 2). High magnification images of the crosssections of hair follicles revealed that the Pla2g2e signal was localized in the second outermost layer and the innermost layer surrounding the growing hair shafts. These results suggest the specific localization of sPLA 2 -IIE in companion cells of the outer root sheath (ORS) and cuticular cells of the inner root sheath (IRS) in hair follicles during anagen.

Skin Phenotypes in Pla2g2e
Ϫ/Ϫ Mice-To assess the roles of sPLA 2 -IIE in mouse skin, we employed Pla2g2e Ϫ/Ϫ mice (24). Grossly, Pla2g2e Ϫ/Ϫ mice over 1 year of age under normal housing conditions had a normal appearance with no apparent skin abnormality. Histologically, the skins of both genotypes showed no apparent differences in the density and length of hair follicles, thickness of the dermis and epidermis, and organization of the subcutaneous fat layer between the skins of both genotypes at P33 (Fig. 3A). We noticed, however, that the upper part of growing hair follicles, where sPLA 2 -IIE was located (Fig.  2), appeared to be swollen in Pla2g2e Ϫ/Ϫ mice relative to Pla2g2e ϩ/ϩ mice.
To clarify the subtle skin alterations caused by Pla2g2e ablation, we performed microarray analysis using Pla2g2e Ϫ/Ϫ skin in comparison with Pla2g2e ϩ/ϩ skin at this stage. We also compared the gene expression profile in Pla2g2e Ϫ/Ϫ skin with that in age-matched Pla2g2f Ϫ/Ϫ skin, which displayed only modest epidermal abnormalities under normal conditions (19). Indeed, there were only a few alterations of gene expression in normal skin of Pla2g2f Ϫ/Ϫ mice relative to that of WT mice at this stage ( Fig. 3B). Similarly to Pla2g2f Ϫ/Ϫ skin, the global gene expression profile was not profoundly affected in Pla2g2e Ϫ/Ϫ skin. We found, however, that the expression levels of a subset of genes (e.g. S100a9, Defb8, Sprr2f, Serpine1, Adam8, Klk6, Il1b, Il1f6, and Ccl5), which are reportedly elevated in response to epidermal stress (25)(26)(27)(28)(29)(30), were substantially higher in Pla2g2e Ϫ/Ϫ skin than in control skin (Fig. 3B). The microarray results were further verified by quantitative RT-PCR, in which the expression of S100a9 and Klk6 was significantly higher, whereas that of Camp was lower, in Pla2g2e Ϫ/Ϫ skin than in Pla2g2e ϩ/ϩ skin (Fig. 3C). Increased expression of Krt14, but not Krt1, in Pla2g2e Ϫ/Ϫ skin (Fig. 3C) implies that the lack of sPLA 2 -IIE has some influence on hair follicular and/or basal keratinocytes rather than on suprabasal keratinocytes. However, the state of the inside-out skin barrier, as assessed by transepidermal water loss (TEWL), did not differ between Pla2g2e Ϫ/Ϫ and Pla2g2e ϩ/ϩ skins (Fig. 3D), suggesting that the modest changes in the expression of a subset of skin genes did not affect epidermal barrier function in Pla2g2e Ϫ/Ϫ mice. Notably, expression of specific keratins (Krt16 and its partners Krt6a and Krt6b), which are preferentially distributed in the companion layer of hair follicles (31)(32)(33), was uniquely elevated in Pla2g2e Ϫ/Ϫ skin relative to Pla2g2e ϩ/ϩ skin (Fig. 3B). Quantitative RT-PCR confirmed the increased expression of Krt16, Krt6a, and Krt6b in Pla2g2e Ϫ/Ϫ skin relative to Pla2g2e ϩ/ϩ skin, although the expression of other hair keratins was unaffected by Pla2g2e deficiency (Fig. 3E). Thus, in agreement with the main localization of sPLA 2 -IIE in hair follicles ( Fig. 1), Pla2g2e Ϫ/Ϫ skin harbors some alterations in the expression of several, if not all, hair follicular genes.
Transmission electron microscopy revealed notable abnormalities in hair follicles (Fig. 4, A and B), rather than epidermis (data not shown), in Pla2g2e Ϫ/Ϫ mice. The hair follicle consists of several distinctive layers as follows: ORS, companion layer, IRS (Henle's layer, Huxley's layer, and IRS cuticle), and hair shaft (cuticle, hair cortex, and medulla) from the outermost to innermost layers. In contrast to the well organized architecture of hair follicles in WT mice, those in Pla2g2e Ϫ/Ϫ mice had noticeable defects in the IRS and hair shaft (Fig. 4B). In hair follicles of Pla2g2e Ϫ/Ϫ skin, IRS cells contained large cytoplas-mic cysts and pyknotic nuclei and were devoid of keratohyalin granules. Adjacent to the cuticle, Pla2g2e Ϫ/Ϫ mice had unusual pericuticular cells that were absent in WT mice, suggesting altered differentiation of hair follicular cells. Moreover, the cuticle in Pla2g2e Ϫ/Ϫ mice was abnormally dissociated from the hair cortex and medulla, which had an immature or regressed appearance. These results appear to be compatible with the swollen feature of Pla2g2e Ϫ/Ϫ hair follicles under the light microscope (Fig. 3A). Thus, the lack of sPLA 2 -IIE leads to hair follicle abnormalities.
No Alterations of Psoriasis and Contact Dermatitis in Pla2g2e Ϫ/Ϫ Mice-In psoriasis and skin cancer, sPLA 2 -IIF is up-regulated in the thickened epidermis and promotes epidermal hyperplasia through production of the unique lysophospholipid P-LPE (19). Some alterations in Pla2g2e Ϫ/Ϫ skin under normal conditions (Figs. 3, 4) prompted us to examine the impact of Pla2g2e deficiency on these skin disorders. However, neither imiquimod (IMQ)-induced psoriasis nor dinitrofluorobenzene (DNFB)-induced contact dermatitis was affected in Pla2g2e Ϫ/Ϫ mice in comparison with Pla2g2e ϩ/ϩ mice (Fig. 5,  A and B). This was in contrast to Pla2g2f Ϫ/Ϫ mice, where ear swelling was significantly ameliorated in both models. Moreover, although the level of P-LPE, a main metabolite produced by sPLA 2 -IIF, was selectively reduced in IMQ-treated Pla2g2f Ϫ/Ϫ skin relative to WT mice as reported previously (19), the levels of P-LPE as well as other lipid metabolites were similar in the psoriatic skins of Pla2g2e Ϫ/Ϫ and WT mice (Fig.  5C). Thus, unlike sPLA 2 -IIF that promotes epidermal hyperplasia (19), sPLA 2 -IIE plays a minimal role in these skin disorders, further emphasizing the functional segregation of these two sPLA 2 s in the skin. sPLA 2 -IIE-dependent Lipid Metabolism in Mouse Skin-To identify the lipid metabolism that potentially lies downstream of sPLA 2 -IIE in mouse skin, we performed electrospray ionization mass spectrometry (ESI-MS) lipidomics analysis using Pla2g2e Ϫ/Ϫ mice in comparison with littermate WT mice at P8 and P33, at which time (corresponding to the initial and next anagens, respectively) sPLA 2 -IIE expression in the skin was very high (Fig. 1B). We found that the skin levels of free PUFAs, including LA, AA, and docosahexaenoic acid (DHA), were significantly lower in Pla2g2e Ϫ/Ϫ mice than in age-matched Pla2g2e ϩ/ϩ mice (Fig. 6A). Among the lysophospholipids, there were notable reductions of the acyl and plasmalogen forms of LPE in Pla2g2e Ϫ/Ϫ skin relative to age-matched Pla2g2e ϩ/ϩ skin, although the levels of other lysophospholipids, including lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC), were not profoundly affected by Pla2g2e deficiency (Fig.  6B). Despite the decreases of free PUFAs in Pla2g2e Ϫ/Ϫ skin, however, the levels of various PUFA metabolites, many if not all of which increased with age probably due to increased expression of epidermal lipoxygenases (34), did not differ significantly between the genotypes, except that 10-hydroxydocosahexaenoic acid was lower at P8 and protectin D1 was greater at P33 in Pla2g2e Ϫ/Ϫ skin than in WT skin (Fig. 6C). Although the reason for a trend toward the increase of protectin D1 at P33 in Pla2g2e Ϫ/Ϫ skin relative to WT skin is unknown, it might reflect a compensatory response. Phospholipid species did not noticeably differ between the genotypes (data not shown), likely because high background levels of phospholipids in membranes of the whole skin masked their local changes by sPLA 2 s in a subset of cells. Altogether, these results suggest that sPLA 2 -IIE mobilizes various PUFA and LPE species, but with few effects on PUFA metabolites, in mouse skin.
Enzymatic Properties of sPLA 2 -IIE toward Skin-extracted Phospholipids-The enzymatic activity of sPLA 2 -IIE has remained controversial. Suzuki et al. (23) have shown that the activity of sPLA 2 -IIE is nearly comparable with that of sPLA 2 -IIA, being capable of hydrolyzing phosphatidylethanolamine and to a lesser extent phosphatidylcholine with no fatty acid selectivity, whereas Valentin et al. (22) have reported that the activity of sPLA 2 -IIE is much weaker than that of other sPLA 2 s. To assess whether sPLA 2 -IIE is indeed able to release PUFAs and LPEs from skin phospholipids, we incubated recombinant sPLA 2 -IIE with two different concentrations of skin-extracted phospholipids in vitro. We found that the activity of sPLA 2 -IIE was robust when the substrate concentration was high (10 M), whereas it was very weak at a low substrate concentration (1 M) (Fig. 7, A and B). In the presence of 10 M substrate, sPLA 2 -IIE released various unsaturated fatty acids, including oleic acid, LA, AA, and DHA, as well as LPE(18:0) in preference to LPC(18:0) (Fig. 7, A and B). In comparison, sPLA 2 -IIF and sPLA 2 -V were sufficiently active even at 1 M substrate (Fig. 7, C and D), as monitored by the release of their preferred fatty acids (DHA and oleic acid, respectively) and lysophospholipids (LPE(18:0) and LPC(18:0), respectively) (19,24). As for LPE molecular species, sPLA 2 -IIE released various LPE species (acyl and plasmalogen forms), whereas sPLA 2 -IIF tended to release P-LPE in preference to acyl-LPE (Fig. 7E). These results suggest that sPLA 2 -IIE is as active as other sPLA 2 s if the phospholipid concentration is high enough or that the skin-extracted phospholipid preparation used in this assay might have contained a certain substance that enhances the activity of sPLA 2 -IIE. The overall enzymatic properties of sPLA 2 -IIE observed here are roughly reminiscent of those reported by Suzuki et al. (23) and are consistent with the lipid profiles that are altered in Pla2g2e Ϫ/Ϫ skin in vivo (Fig. 6).

Discussion
Our recent study using Pla2g2f-deficient and -transgenic mice, in combination with PLA 2 -directed lipidomics toward phospholipids (substrate) as well as fatty acids, lysophospholipids, and their metabolites (products), has revealed a unique and novel lysophospholipid pathway driven by sPLA 2 -IIF that promotes keratinocyte activation and epidermal hyperplasia (19). In this study, we have identified sPLA 2 -IIE as the second sPLA 2 that is abundantly expressed in mouse skin. Unlike sPLA 2 -IIF, an epidermal sPLA 2 that is expressed in differentiated epidermal keratinocytes (19), sPLA 2 -IIE is regarded as a "hair follicular sPLA 2 " that is enriched in hair follicles in the anagen phase of hair cycling.
So far, except for its metabolic role in diet-induced obesity in adipose tissue (24), sPLA 2 -IIE is an ill-characterized sPLA 2 whose expression, enzymatic properties, and in vivo functions remain poorly understood. Our present finding that sPLA 2 -IIE is abundantly expressed in mouse skin (at an even higher level than sPLA 2 -IIF during anagen), together with the fact that sPLA 2 -IIE (as is sPLA 2 -IIF, but not other sPLA 2 s) is enzymatically active at a mildly acidic pH relevant to the skin microenvironment (22), suggests that sPLA 2 -IIE plays some roles in skin pathophysiology. It should be noted, however, that the skin compartments in which sPLA 2 -IIE and -IIF are localized are distinct. sPLA 2 -IIF is expressed in the suprabasal epidermis and is dramatically up-regulated during terminal differentiation or   (19), whereas sPLA 2 -IIE is expressed constantly in basal keratinocytes. More importantly, sPLA 2 -IIE is expressed in hair follicles much more abundantly than in the epidermis and in fact sPLA 2 -IIE is the primary hair follicular sPLA 2 whose expression is correlated with hair cycling. These distributions suggest distinct, rather than redundant, roles of these two sPLA 2 s in specific compartments of the skin.
Although grossly Pla2g2e Ϫ/Ϫ mice have a nearly normal appearance, their hair follicles display several abnormalities in terms of ultrastructure and gene expression profile. These abnormalities include the presence of unusual cytoplasmic cysts in the IRS, dissociation of the cuticle from the hair cortex, immaturity or regression of the hair shaft, and altered expres-sion of a subset of keratins associated with the companion layer. Notably, sPLA 2 -IIE is located in these affected regions (the innermost IRS layer and the companion layer along growing hairs) within hair follicles, lending further support to the idea that sPLA 2 -IIE regulates hair follicle homeostasis at these restricted locations. We previously reported that Pla2g10transgenic mice displayed alopecia with perturbed hair cycling and that Pla2g10 Ϫ/Ϫ mice showed ORS hypoplasia (21). However, the very low expression of endogenous sPLA 2 -X in mouse skin argues against its hair follicle-intrinsic role. Rather, we prefer the idea that sPLA 2 -X expressed in distal locations, such as the gastrointestinal tract (35, 36), might indirectly affect hair follicle homeostasis through nutritional or other mechanisms.  In the epidermis, sPLA 2 -IIF is expressed more abundantly than sPLA 2 -IIE. Pla2g2f deficiency increases TEWL (indicating a skin barrier defect) due to SC fragility against environmental stress (19) but with only a few changes in the steady-state expression of skin genes under normal conditions. In contrast, Pla2g2e ablation leads to increased (albeit modest) expression of a panel of genes for the epidermal stress response, without alteration of TEWL. Furthermore, Pla2g2f Ϫ/Ϫ mice display attenuated psoriasis or contact dermatitis with a concomitant reduction of the lysophospholipid P-LPE (19), whereas skin edema and lipid profiles in these disease models are barely affected in Pla2g2e Ϫ/Ϫ mice. These differences can be explained, at least in part, by distinct localizations of these two sPLA 2 s in skin niches (see above) as well as by their distinct substrate specificities (see below), which could have different impacts on epidermal homeostasis and diseases. This view also contrasts with the exacerbation of psoriasis and contact dermatitis with augmented Th1/Th17 immune responses in mice lacking sPLA 2 -IID, a "resolving sPLA 2 " that is expressed in dendritic cells and regulates the functions of immune cells rather than keratinocytes by producing 3 PUFA-derived pro-resolving lipid mediators (37,48).
In contrast to sPLA 2 -IIF, which selectively mobilizes P-LPE in psoriatic skin (19), sPLA 2 -IIE appears to mobilize various unsaturated fatty acids and LPEs (both acyl and plasmalogen forms) in normal skin. Consistent with these in vivo data, sPLA 2 -IIE releases these fatty acids and LPEs in an in vitro enzyme assay using a skin-extracted phospholipid mixture as a substrate. Given its spatiotemporal localization, it is tempting to speculate that sPLA 2 -IIE supplies unsaturated fatty acids and LPEs in hair follicles during anagen. It has been reported that several PUFA metabolites (e.g. prostaglandins) or LPA variably affect hair growth, quality, and cycling (13, 38 -41). However, the skin levels of PUFA metabolites and LPA are not profoundly affected by Pla2g2e deficiency, indicating that sPLA 2 -IIE-derived PUFAs are largely uncoupled with downstream lipid mediators. The issue of whether PUFAs themselves, LPEs, or some other lipid metabolites not examined in this study underlie sPLA 2 -IIE-regulated hair follicle homeostasis will require further investigation.
The assessment of in vitro enzyme activity using recombinant sPLA 2 is influenced by the assay conditions employed, such as the composition of the substrate phospholipids (pure phospholipid vesicles or mixed micelles comprising multiple phospholipid species), the concentrations of sPLA 2 , the presence of detergents, pH, and so on. Therefore, the enzymatic properties of sPLA 2 s determined in different studies are not entirely identical (22,23). Because membranes containing a sin- gle phospholipid species do not exist in vivo, a result obtained using artificial phospholipid membranes may not mirror the in vivo actions of a given sPLA 2 . Ideally, sPLA 2 activity should be evaluated with a physiologically relevant membrane on which the enzyme acts intrinsically, as we have recently reported for sPLA 2 -IIF (19). Nonetheless, the overall selectivity of sPLA 2 s for various phospholipid headgroups and fatty acyl chains has been recapitulated by several in vitro enzymatic studies, and the in vivo lipidomics data have revealed even more selective patterns of hydrolysis (19,24,36,37). Although the local concentration of sPLA 2 -IIE in hair follicles is unclear, our present results obtained from the in vitro and in vivo lipidomics approaches have provided a consistent result, implying that the in vitro activity of sPLA 2 -IIE may be physiologically relevant (at least in the skin).
In conclusion, our current studies have revealed non-redundant and unique roles of the two particular sPLA 2 s, IIE and IIF, in mouse skin. Although the epidermal expression of sPLA 2 -IIF is relevant to humans (19), we currently have no evidence that sPLA 2 -IIE is expressed in human skin. Instead, its closest homolog, sPLA 2 -IIA, is expressed in human skin (19) as well as in human adipose tissue (24). Presumably, in certain if not all situations, the functions of sPLA 2 -IIA in humans might be substituted by those of sPLA 2 -IIE in mice, in which sPLA 2 -IIA expression is limited to the intestine (e.g. BALB/c) or not expressed at all due to a frameshift mutation (e.g. C57BL/6) (42). This notion is supported by the fact that sPLA 2 -IIE is induced in several mouse tissues following lipopolysaccharide challenge (23), an event that has been well documented for sPLA 2 -IIA in humans with inflammation or endotoxin shock (43,44). Alternatively, considering the hair follicle location of sPLA 2 -IIE in mice, the failure to detect sPLA 2 -IIE in human skin may simply be because the human body is not covered with fur. In this context, the spatiotemporal expression of sPLA 2 -IIE and other sPLA 2 s in healthy or diseased human skin would need careful evaluation in the context of epidermal prolifera-tion, differentiation and activation, wound healing, inflammation, hair cycling, and aging. Given that millions of patients are suffering from chronic skin disorders, which can be caused by various factors, including genetic mutations, immunological abnormalities, hormonal imbalances, psychological stresses, or environmental exposures, full elucidation of the lipid networks regulated by sPLA 2 s would assist the search for novel treatments of skin diseases.

Experimental Procedures
Mice-All mice were housed in climate-controlled (23°C) specific pathogen-free facilities with a 12-h light-dark cycle, with free access to standard laboratory food (CE2 Laboratory Diet, CLEA, Japan) and water. Pla2g2e Ϫ/Ϫ and Pla2g2f Ϫ/Ϫ mice, backcrossed to C57BL/6 or BALB/c mice (Japan SLC) for more than 12 generations, were described previously (19,24). All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committees of the Tokyo Metropolitan Institute of Medical Science in accordance with the Japanese Guide for the Care and Use of Laboratory Animals.
Quantitative RT-PCR-Total RNA was extracted from tissues and cells using TRIzol reagent (Invitrogen). First-strand cDNA synthesis was performed using a high capacity cDNA reverse transcriptase kit (Applied Biosystems). PCRs were carried out using a Power SYBR Green PCR system (Applied Biosystems) or a TaqMan Gene Expression System (Applied Biosystems) on the ABI7300 Quantitative PCR system (Applied Biosystems). The probe/primer sets used are listed in Table 1.
TaqMan Rodent GAPDH control reagents (4308313) thick cryosections. The stained sections were analyzed with a BX61 microscope (Olympus). Epidermal thickness was measured using DP2-BSW software (Olympus). Microdissection-Mouse skin samples (P8) were embedded in OCT compound, sectioned (10-m thick), mounted on DIRECTOR LMD slide (AMR Inc.), fixed with cold ethanol/ acetic acid (19:1, v/v) for 5 min, and stained with toluidine blue. Laser-capture microdissection was performed on cryosections using Leica LMD6000 system (Leica). mRNA was extracted using RNeasy micro kit (Qiagen) from the isolated hair follicle or epidermis fraction.
In Situ Hybridization-Mouse Pla2g2e cDNA was subcloned into the pGEMT-Easy vector (Promega), and used for generation of sense and antisense RNA probes. Digoxigenin labeled-RNA probes were prepared with digoxigenin RNA labeling Mix (Roche Applied Science). Paraffin-embedded sections of mouse skin (6-m thick) were hybridized with the digoxigenin-labeled RNA probes at 60°C for 16 h (Genostaff). The bound label was detected using the alkaline phosphate color substrates 5-bromo-4-chloro-3Ј-indolyl phosphate p-toluidine and nitro blue tetrazolium chloride. The sections were counterstained with Kernechtrot (Muto Pure Chemicals).
IMQ-induced Psoriasis-Mice (BALB/c background, 8 -12week-old males) received a daily topical application of 12.5 mg of 5% (w/v) IMQ (Mochida Pharma) on the dorsal and ventral surfaces of the ears over 4 days (total 50 mg of IMQ cream per mouse). Ear thickness was monitored at various time points with a micrometer, as described previously (19).
Microarray Analysis-Total RNA extracted from skins was purified using the RNeasy mini kit (Qiagen). The quality of RNA was assessed with a 2100 Bioanalyzer (Agilent Technologies). cRNA targets were synthesized and hybridized with Whole Mouse Genome Microarray according to the manufacturer's instructions (Agilent Technologies). The array slides were scanned using a Laser Scanner GenePix 4000B (Molecular Devices) or a SureScan Microarray Scanner (Agilent Technologies). Microarray data were analyzed with GenePix software (Molecular Devices) or Agilent's Feature Extraction software. The GEO accession number for microarray is GSE80418.
ESI-MS-Samples for ESI-MS of lipids were prepared and analyzed as described previously (19,37). In brief, for detection of phospholipids, tissues were soaked in 10 volumes of 20 mM Tris-HCl (pH 7.4) and then homogenized with a Polytron homogenizer. Lipids were extracted from the homogenates by the method of Bligh and Dyer (45). The analysis was performed using a 4000Q-TRAP quadrupole-linear ion trap hybrid mass spectrometer (AB Sciex) with liquid chromatography (NexeraX2 system; Shimazu). The samples were applied to a Kinetex C18 column (1 ϫ 150-mm inner diameter, 1.7-m particle) (Phenomenex) coupled for ESI-MS/MS. The samples injected by an autosampler (10 l) were separated by a step gradient with mobile phase A (acetonitrile/methanol/water ϭ 1:1:1 (v/v/v) containing 5 M phosphoric acid and 1 mM ammonium formate) and mobile phase B (2-propanol containing 5 M phosphoric acid and 1 mM ammonium formate) at a flow rate of 0.2 ml/min at 50°C. For detection of fatty acids and their oxygenated metabolites, tissues were soaked in 10 volumes of methanol and then homogenized with a Polytron homogenizer. After overnight incubation at Ϫ20°C, water was added to the mixture to give a final methanol concentration of 10% (v/v). As an internal standard, 1 nmol of d 5 -labeled eicosapentaenoic acid and d 4 -labeled prostaglandin E 2 (Cayman Chemicals) was added to each sample. The samples in 10% methanol were applied to Oasis HLB cartridges (Waters), washed with 10 ml of hexane, eluted with 3 ml of methyl formate, dried up under N 2 gas, and dissolved in 60% methanol. The samples were then applied to a Kinetex C18 column (1 ϫ 150-mm inner diameter, 1.7 m particle) (Phenomenex) coupled for ESI-MS/MS as described above. The samples injected by an autosampler (10 l) were separated using a step gradient with mobile phase C (water containing 0.1% acetic acid) and mobile phase D (acetonitrile/methanol ϭ 4:1; v/v) at a flow rate of 0.2 ml/min at 45°C. Identification was conducted using multiple reaction monitoring transition and retention times, and quantification was performed based on peak area of the multiple reaction monitoring transition and the calibration curve obtained with an authentic standard for each compound, as described previously (19,37). PLA 2 Enzyme Assay Using Skin-extracted Phospholipids-PLA 2 assay was performed using skin-extracted phospholipids and pure recombinant human sPLA 2 s, as described previously (19). In brief, total phospholipids were extracted from mouse skin as above and further purified by straight-phase chromatography. The samples extracted in chloroform were applied to a Sep-Pak Silica Cartridge (Waters), washed sequentially with acetone and chloroform/methanol (9/1; v/v), eluted with chlo-roform/methanol (3/1; v/v), and dried under an N 2 gas. The amounts of total phospholipids in samples were determined by the inorganic phosphorous assay (46). The membrane mimic composed of tissue-extracted lipids (1-10 M) was sonicated for 5 min in 100 mM Tris-HCl (pH 7.4) containing 4 mM CaCl 2 and then incubated for appropriate periods with 10 ng of recombinant sPLA 2 s (47) at 37°C for 30 min. After incubation, the lipids were mixed with internal standards, extracted, and subjected to liquid chromatography-MS for detection of fatty acids and lysophospholipids, as noted above.
Statistical Analyses-All values are given as the means Ϯ S.E. Differences between the two groups were assessed by unpaired Student's t test using the Excel Statistical Program File ystat 2008 (Igaku Tosho Shuppan, Tokyo, Japan). Differences at p values of less than 0.05 were considered statistically significant.